Regeneron price target raised to $1,050 from $1,020 at Barclays

Barclays analyst Carter Gould raised the firm’s price target on Regeneron to $1,050 from $1,020 and keeps an Overweight rating on the shares. The company’s Q4 earnings call “lacked suspense” with the Eylea and Dupi prints largely already known, and the 2024 guide coming in in-line with expectations, the analyst tells investors in a research note.